Breast Cancer Recurrence
The results of the Oncotype DX® test (for invasive breast cancer) are provided as a breast cancer Recurrence Score® result, a number between 0 and 100. This number corresponds to a specific likelihood that a woman's breast cancer will spread to another area of her body within 10 years of her initial diagnosis. The lower the score is, the lower the chances are that a woman's breast cancer will come back, and the higher the score, the greater the chances that breast cancer will come back.
In addition, the Oncotype DX test provides information about a woman's likelihood of benefiting from commonly used regimens of chemotherapy for breast cancer treatment. Patients with low Recurrence Score results are likely to receive little if any benefit from chemotherapy. Patients with high breast cancer Recurrence Score results are more likely to receive a significant benefit from chemotherapy. This information, together with other information about the chance a woman's breast cancer will return, can help a woman and her doctor make a decision about the treatment that is best for her individual breast cancer.
The Oncotype DX DCIS ScoreTM result (for pre-invasive breast cancer), is a number between 0 and 100. Women with lower DCIS Scores have a lower risk of their cancer returning as a DCIS tumor or as an invasive tumor. However, this does not mean that there is no chance of the cancer returning. Similarly, a higher DCIS Score means that there is a greater chance of the cancer returning. A higher score does not mean that the cancer will definitely return. The test can also help doctors determine the likelihood of DCIS returning or the tumor returning as invasive breast cancer in the same location, also known as local recurrence.
Some additional information the Oncotype DX test will provide are the activity levels of estrogen and progesterone. All of these figures will help your doctor recommend the appropriate treatment plan.
Your doctor is a valuable resource for helping you better understand the meaning of each section of your report.
The information provided by the Oncotype DX test can help increase doctors' and patients' confidence in and satisfaction with their breast cancer treatment decisions, as shown in recent studies.
Multi-Center Study of Oncologist And Invasive Breast Cancer Patient Decision Making*
- About one-third of physicians changed their invasive breast cancer treatment recommendation after receiving the Recurrence Score result
- The Recurrence Score result increased physicians' confidence in their breast cancer treatment recommendation 1
- About one-third of patients changed their choice of invasive breast cancer treatment based on their Recurrence Score result
- Patients reported significantly lower conflict about their invasive breast cancer treatment decision and greater satisfaction with that decision
- Patients' anxiety levels decreased after they learned their Recurrence Score result
- The majority of patients felt that their Recurrence Score result influenced their breast cancer treatment decision and were glad they took the test 1
Journal of Oncology Practice Study
- For about one-fourth of patients, knowledge of the Recurrence Score result changed physicians' treatment recommendations and eventual breast cancer treatment
- The decision to change from hormone therapy to chemotherapy (with or without hormone therapy) was generally associated with a high Recurrence Score result, while the decision to change from chemotherapy to hormone therapy was generally associated with a low Recurrence Score result 2
Additional Breast Cancer Studies
- Chemotherapy was usually not given to breast cancer patients with low Recurrence Score results, and was generally given to patients with high Recurrence Score results 3
- The overall use of chemotherapy in the invasive breast cancer patient population studied declined by more than 50% after the use of Oncotype DX began 3
- Patients with low Recurrence Score results were generally treated with hormone therapy alone and rarely received chemotherapy 4
Back to Top
Validation studies have already been performed on the Oncotype DX Breast Cancer Assay for patients with pre-invasive or DCIS, node-negative and node-positive, estrogen-receptor-positive (ER+) breast cancer; for single gene reporting quantitative of ER (estrogen receptor), PR (progesterone receptor negative) and HER2 (human epidermal growth factor receptor 2) genes, and for patients treated with Tamoxifen or an Aromatase Inhibitor. The Oncotype DX breast cancer tests are currently commercially available. For detailed information please call: (866) ONCOTYPE or visit www.oncotypedx.com
*For invasive disease.
- Lo SS, Norton J, Mumby PB, et al. Prospective multi-center study of the impact of the 21-gene Recurrence Score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection. Presented at the Forty-third Meeting of the American Society of Clinical Oncology. June 1-5, 2007; Chicago, IL. Abstract #577.
- Oratz R, Paul D, Cohn AL, et al. Impact of a commercial reference laboratory Recurrence Score on decision making in early-stage breast cancer. J Onc Pract. 2007;3(4):182-6.
- Erb C, Fox KR, Patel M, et al. Evaluation of practice patterns in the treatment of node-negative, hormone-receptor positive breast cancer patients with the use of the Oncotype DX assay at the University of Pennsylvania. Presented at the 30th Annual San Antonio Breast Cancer Symposium. December 13-16, 2007; San Antonio, TX. Abstract #3082.
- Liang H, Brufsky AM, Lembersky BC, et al. A retrospective analysis of the impact of Oncotype DX low Recurrence Score results on treatment decisions in a single academic breast cancer center. Presented at the 30th Annual San Antonio Breast Cancer Symposium. December 13-16, 2007; San Antonio, TX. Abstract #2061.